Are the "Cardiac Benefits" of Empagliflozin Independent of Its Hypoglycemic Activity? (ATRU-4).

NCT03485222 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

84

Enrollment

OTHER

Sponsor class

Conditions

Cardiovascular Diseases

Interventions

DRUG: Empagliflozin
DRUG: Placebos

Sponsor

Icahn School of Medicine at Mount Sinai

Collaborators

[object Object]
[object Object]